MPM Capital
PE / VC · Boston · United States
Stages
Investment region
Industries
Profile
MPM Capital is a venture capital firm focusing on healthcare and biotechnology, based in the United States. With over 30 years of experience, MPM Capital has played a pivotal role in the development of more than 60 FDA-approved drugs and facilitated over 120 M&A and IPO events. The firm is led by a team of seasoned professionals, including Ansbert Gadicke, M.D., Chairman, and Joseph Bolen, Ph.D., CEO. MPM Capital is distinguished by its commitment to transforming scientific breakthroughs into life-saving medicines. The firm invests in private and public companies throughout the drug development process. MPM Capital's sector focus includes biotechnology, pharmaceuticals, MedTech, and life sciences. It supports series A through late-stage investments, primarily across North America. MPM Capital has accumulated substantial assets under management over its years of operation. Notable portfolio companies of MPM Capital include Orna Therapeutics - circular RNA medicines, Aktis Oncology - radiopharmaceuticals for cancer treatment, Reunion - psychedelic-inspired pharmaceuticals for mental health, and argenx - immunology-focused biotech. Orna was notably acquired by Lilly for up to $2.4 billion.
担当者 (2)
| Name | Title | 電話 | ||
|---|---|---|---|---|
| Entrepreneur Partner | — | — | — | |
| Managing Director, Chief Financial Officer and Chief Operating Officer | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.